What is the 13F Pro Quality Score for LH?

13F Pro ranks LABCORP HOLDINGS INC. (LH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LH's current score at https://13fpro.ai/company/LH (free sign-up required for the full ranking).

Where does 13F Pro source LH data?

All LABCORP HOLDINGS INC. fundamentals and ownership data come directly from SEC EDGAR. LABCORP HOLDINGS INC. files with the SEC under CIK 920148. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LH in?

LABCORP HOLDINGS INC. (LH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives LH's revenue?

Per LABCORP HOLDINGS INC.'s latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: Diagnostics Laboratories (Dx) ($2,900.7M, +5.5% YoY); Biopharma Laboratory Services (BLS) ($836.2M, +6.5% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/LH.

What are LH's largest expenses?

LABCORP HOLDINGS INC.'s latest 10-Q reports these as the largest expense items: Cost of revenues ($2,619.1M, +5.6% YoY); Selling, general, and administrative expenses ($577.2M, -0.3% YoY); Amortization of intangibles and other assets ($78.1M, +14.3% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is LH research updated on 13F Pro?

LH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

LABCORP HOLDINGS INC.(LH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 920148 LH stock profile & AI dashboard →

13F Pro Quality Score

65.0/100

Rank #513 of 2,960 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

50.8/100

Profitability

59.4/100

Balance Sheet

72.4/100

Earnings Quality

77.2/100

Free Cash Flow

50.8/100

Institutional Flow

73.5/100

Revenue Scale

89.6/100

Dilution Risk

60.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why LH Scores 65/100

exact factor attribution · 2026-09-12

LH's composite is driven by scale and earnings quality. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+5.9 pts

90th pct

Earnings quality

+2.7 pts

77th pct

Capital efficiency

+2.2 pts

72th pct

Profitability

+1.4 pts

59th pct

Institutional flow

+1.2 pts

74th pct

Earnings growth

+0.7 pts

64th pct

Shareholder dilution

+0.5 pts

60th pct

Revenue growth

+0.2 pts

51th pct

Free cash flow

+0.1 pts

51th pct

Latest change (2026-08-06): 55 → 61 · ↑ Revenue growth 17→46; ↑ Earnings growth 38→74; despite ↓ Free cash flow 52→38

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

LH Stock Analysis & AI Quality Score

Data updated 2026-09-12

AI stock analysis and institutional research for LABCORP HOLDINGS INC. (LH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LH at 65.0/100 on a 32-signal composite quality model, placing it at rank #513 of 2,960 stocks — the top 25% of the AI-ranked universe. LH scores in the top quartile across revenue scale (89.6), earnings quality (77.2). Based on the latest XBRL financial filings (Q2 2026), LABCORP HOLDINGS INC. reports quarterly revenue of $3.7B, net income of $298.7M, an operating margin of 12.1%. Top institutional holders of LH by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VICTORY CAPITAL MANAGEMENT, based on the most recent SEC filings. LH trades on the NYSE exchange and files with the SEC under CIK 920148. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LABCORP HOLDINGS INC. directly from SEC EDGAR. LABCORP HOLDINGS INC.'s 13F Pro composite quality score has ranged between 44 and 68 since 2024, currently 65.0 — an improving long-term trajectory across 57 quarterly and live scoring snapshots.

✦

Fun facts about LABCORP HOLDINGS INC.

Quirks, history, and lore behind LH — the kind of stuff that makes a stock memorable.

1
The Basics
A U.S. healthcare company · large-cap · listed on the NYSE · headquartered in North Carolina.
2
The Numbers
Annual revenue of roughly $15 billion, processing hundreds of millions of tests each year — one of the highest-volume lab operations on the planet.
3
The History
Born from a 1995 merger of two rival clinical lab networks, it grew through decades of acquisitions into a near-duopoly alongside one well-known competitor.
4
The Secret
It's not just blood draws — the company also runs one of the largest drug development and clinical trial testing businesses in the world.
5
The Lore
During the COVID-19 pandemic, it became a household name by processing millions of coronavirus tests, suddenly famous for something most people never thought about before.
6
The Giveaway
You've almost certainly had your blood work sent here — they operate thousands of patient service centers nationwide under a name that rhymes with 'lab corp.'

▶ Think you know your stocks? Play the Daily Ticker

What's Driving LH's Business? Latest 10-Q Breakdown

✓ 33/33 datapoints verified

AI-extracted from LABCORP HOLDINGS INC.'s 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Labcorp grew Q2 FY2026 revenue 5.8% YoY to $3,731.1M as both segments expanded operating margins — Dx +50bps to 18.0%, BLS +130bps to 17.0% — driving operating income up 14.5% to $451.6M.

Biggest Revenue Drivers

Diagnostics Laboratories (Dx)$2,900.7M+5.5% YoY

Organic revenue growth of 3.6% plus acquisitions, net of divestitures, of 1.9%; volume up 3.0% and price/mix up 2.5%

Biopharma Laboratory Services (BLS)$836.2M+6.5% YoY

Organic growth of 6.2% and favorable FX of 1.8%, partly offset by a 1.4% drag from strategic actions in Early Development

Biggest Revenue Drivers

Total revenue: $3,731.1M+5.8% YoY

Diagnostics Laboratories (Dx)$2,900.7M+5.5% YoY

Organic revenue growth of 3.6% plus acquisitions, net of divestitures, of 1.9%; volume up 3.0% and price/mix up 2.5%

Biopharma Laboratory Services (BLS)$836.2M+6.5% YoY

Organic growth of 6.2% and favorable FX of 1.8%, partly offset by a 1.4% drag from strategic actions in Early Development

Largest Expense Items

Cost of revenues$2,619.1M+5.6% YoY

Ratio improved to 70.2% of revenue from 70.3%, due to organic growth and operating efficiencies, partly offset by higher personnel costs

Selling, general, and administrative expenses$577.2M-0.3% YoY

Ratio improved to 15.5% of revenue from 16.4%, primarily due to revenue growth

Amortization of intangibles and other assets$78.1M+14.3% YoY

Reflects additional amortization for assets acquired subsequent to June 30, 2025

Restructuring and other charges$5.1M+21.2% YoY

Comprised of severance, facility, and contract termination costs, partly offset by reversal of unused prior liabilities

Margins: Cost of revenues fell to 70.2% of revenue from 70.3% and SG&A fell to 15.5% from 16.4%, both aided by organic revenue growth and operating efficiencies; operating income rose 14.5% YoY to $451.6M with Dx and BLS segment margins each expanding.

Watch Items from the Filing

Ravgen Inc. patent infringement verdict of $272.0M plus $100.0M enhanced damages and an ongoing per-test royalty remains under appeal by the Company.
OBBBA Medicaid/ACA changes could reduce insurance coverage and diagnostics testing utilization, though the Company currently expects no material impact.
Board increased share repurchase authorization by $1,000.0M on July 8, 2026, bringing total authorization to $1,378.6M; $451.8M repurchased in H1 2026.
AMCA data breach class action settlement (entered March 2, 2026) and Meta Pixel tracking class action settlement (entered April 2, 2026) remain subject to court approval.
Approximately 13.9% of six-month revenue is denominated in non-USD currencies (CAD, CHF, EUR, GBP); a hypothetical 10% FX move would have impacted pretax income by ~$17.1M.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$3.7B

Net Income

Q2 2026

$298.7M

Free Cash Flow

Q2 2026

$313.9M

Operating Margin

Q2 2026

12.1%

ROIC

Q2 2026

12.5%

D/E Ratio

Q2 2026

0.68

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+7.2% YoY

$13.95BFY 2025

FY22 $11.86BFY23 $12.16BFY24 $13.01BFY25 $13.95B

Net Income

+17.5% YoY

$876.5MFY 2025

FY22 $1.28BFY23 $418.0MFY24 $746.0MFY25 $876.5M

Operating Income

+27.4% YoY

$1.38BFY 2025

FY22 $1.44BFY23 $725.6MFY24 $1.09BFY25 $1.38B

EPS (Diluted)

+18.3% YoY

$10.46FY 2025

FY22 $13.97FY23 $4.77FY24 $8.84FY25 $10.46

Total Assets

+0.1% YoY

$18.39BFY 2025

FY22 $20.16BFY23 $16.73BFY24 $18.38BFY25 $18.39B

Total Debt

-23.8% YoY

$5.58BFY 2025

FY22 $5.34BFY23 $5.05BFY24 $7.33BFY25 $5.58B

Op. Cash Flow

+3.4% YoY

$1.64BFY 2025

FY22 $1.96BFY23 $1.33BFY24 $1.59BFY25 $1.64B

Free Cash Flow

+10.0% YoY

$1.21BFY 2025

FY22 $1.53BFY23 $874.1MFY24 $1.10BFY25 $1.21B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$13.95B +7.2%	$13.01B +7.0%	$12.16B +2.5%	$11.86B -9.7%	$13.14B -6.0%	$13.98B
Net Income	$876.5M +17.5%	$746.0M +78.5%	$418.0M -67.3%	$1.28B -46.2%	$2.38B +52.8%	$1.56B
Operating Income	$1.38B +27.4%	$1.09B +49.8%	$725.6M -49.5%	$1.44B -52.9%	$3.05B +24.7%	$2.45B
EPS (Diluted)	$10.46 +18.3%	$8.84 +85.3%	$4.77 -65.9%	$13.97 -42.7%	$24.39 +53.6%	$15.88
Total Assets	$18.39B +0.1%	$18.38B +9.9%	$16.73B -17.0%	$20.16B -1.1%	$20.39B +1.6%	$20.07B
Total Debt	$5.58B -23.8%	$7.33B +45.1%	$5.05B -5.3%	$5.34B -1.4%	$5.42B -6.5%	$5.80B
Operating Cash Flow	$1.64B +3.4%	$1.59B +19.4%	$1.33B -32.1%	$1.96B -37.1%	$3.11B +45.6%	$2.14B
Free Cash Flow	$1.21B +10.0%	$1.10B +25.4%	$874.1M -42.7%	$1.53B -43.2%	$2.69B +53.3%	$1.75B

Get alerted when LH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LABCORP HOLDINGS INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LH

BlackRock, Inc.
$1.8B6,574,261 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.5B5,362,254 sh
VICTORY CAPITAL MANAGEMENT INC
$1.4B4,837,573 sh
STATE STREET CORP
$1.1B3,907,656 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.0B3,678,798 sh
Boston Partners
$854.2M3,051,690 sh
Allspring Global Investments Holdings, LLC
$635.0M2,236,957 sh
GEODE CAPITAL MANAGEMENT, LLC
$610.4M2,188,890 sh
Select Equity Group, L.P.
$554.9M1,981,948 sh
FMR LLC
$533.4M1,904,870 sh

Fund	Value	Shares
BlackRock, Inc.	$1.8B	6,574,261
VANGUARD CAPITAL MANAGEMENT LLC	$1.5B	5,362,254
VICTORY CAPITAL MANAGEMENT INC	$1.4B	4,837,573
STATE STREET CORP	$1.1B	3,907,656
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.0B	3,678,798
Boston Partners	$854.2M	3,051,690
Allspring Global Investments Holdings, LLC	$635.0M	2,236,957
GEODE CAPITAL MANAGEMENT, LLC	$610.4M	2,188,890
Select Equity Group, L.P.	$554.9M	1,981,948
FMR LLC	$533.4M	1,904,870

Companies Similar to LH

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

DGX

QUEST DIAGNOSTICS INC

AI score

Very similar · 25 shared holders

Boston Partners Willis Investment Counsel AVIVA PLC

MDT

Medtronic plc

AI score

Very similar · 30 shared holders

Boston Partners HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC DIAMOND HILL CAPITAL MANAGEMENT INC

GEHC

GE HealthCare Technologies Inc.

AI score

Very similar · 31 shared holders

Boston Partners HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC NORDEA INVESTMENT MANAGEMENT AB

ABT

ABBOTT LABORATORIES

AI score

Very similar · 28 shared holders

DIAMOND HILL CAPITAL MANAGEMENT INC BECK MACK & OLIVER LLC NORDEA INVESTMENT MANAGEMENT AB

HCA

HCA Healthcare, Inc.

AI score

Very similar · 30 shared holders

NORDEA INVESTMENT MANAGEMENT AB BRANDES INVESTMENT PARTNERS, LP COOKE & BIELER LP

IQV

IQVIA HOLDINGS INC.

AI score

Very similar · 19 shared holders

Boston Partners EARNEST PARTNERS LLC LORD, ABBETT & CO. LLC

STE

STERIS plc

AI score

Very similar · 25 shared holders

Select Equity Group, L.P.Boston Partners AVIVA PLC

MMM

3M CO

AI score

Very similar · 26 shared holders

Boston Partners Willis Investment Counsel AVIVA PLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LH on your watchlist

Track score changes the day LABCORP HOLDINGS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LH a good stock to buy?

13F Pro's AI-powered analysis of LABCORP HOLDINGS INC. (LH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LH are available on the LH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LH is classified as a large company.

Which hedge funds own LH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LABCORP HOLDINGS INC.'s investment landscape.